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Abstract
Background and Aims—The HALT-C trial demonstrated that low-dose peginterferon
maintenance therapy was ineffective in preventing clinical outcomes in patients with chronic
hepatitis C, advanced fibrosis and failure to achieve a sustained virologic response during lead-in
phase treatment with standard dose peginterferon/ribavirin. This analysis was performed to
determine if suppressing HCV RNA during the trial was associated with a reduction in clinical
outcomes.
Methods—764 patients treated during the lead-in phase of HALT-C were randomized to either
peginterferon alfa-2a (90 mcg/week) maintenance therapy or no treatment (control) for 3.5 years.
Clinical outcomes included an increase in Child-Turcotte-Pugh score, ascites, spontaneous
bacterial peritonitis, hepatic encephalopathy, variceal hemorrhage, hepatocellular carcinoma and
mortality.
Results—During the lead-in, ≥4 log10 decline in serum HCV RNA occurred in 178 patients;
82% of whom lost detectable HCV RNA and later broke through or relapsed. These patients had
significantly (p=0.003) fewer clinical outcomes whether randomized to maintenance therapy or
control. Following randomization serum HCV RNA increased significantly in all 90 control
patients and 58/88 receiving maintenance therapy. Only 30 patients had persistent suppression of
HCV RNA by ≥4 log10 during maintenance therapy. No significant reduction in clinical outcomes
was observed in these patients.
Conclusions—Viral suppression by ≥4 log10 with full dose peginterferon/ribavirin is associated
with a significant reduction in clinical outcomes. Continuing low dose peginterferon maintenance
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therapy, even in patients with persistent viral suppression, does not lead to a further decline in
clinical outcomes.
Peginterferon and ribavirin therapy results in a sustained virologic response (SVR) in
approximately 50% of patients (1,2). Unfortunately, patients with advanced fibrosis or
cirrhosis respond less well to this treatment. Since these patients are at increased risk for
hepatic decompensation, hepatocellular carcinoma (HCC) and mortality new approaches for
managing chronic hepatitis C are needed (3,4). Although liver transplantation is an option
disease recurrence is universal (5,6).
Patients who SVR following treatment of hepatitis C have an improvement in liver histology
and a reduction in liver related mortality (4,7,8,9). Some studies have suggested that even
nonresponders to interferon treatment have a reduced risk of HCC and mortality (10,11).
Moreover, patients with chronic hepatitis C who have a decline in serum HCV RNA during
interferon therapy achieve histologic improvement and these improvements can be
maintained by continuing treatment (12). These collective observations led to the hypothesis
that continuing interferon long-term as maintenance therapy could reduce the risk of hepatic
decompensation, HCC and mortality.
The Hepatitis C Antiviral Long Term Treatment Against Cirrhosis (HALT-C) Trial was a
randomized, controlled study designed to determine if low dose peginterferon alfa-2a
maintenance therapy (90 mcg/week) over 3.5 years could reduce hepatic decompensation,
HCC and mortality in patients with bridging fibrosis or cirrhosis who failed to achieve an
SVR following peginterferon and ribavirin treatment (13). The primary results of this trial
demonstrated that peginterferon maintenance therapy provided no overall benefit (14).
However, it remains unclear if patients who achieved profound viral suppression during
maintenance therapy had a reduction in outcomes. This secondary analysis of data from the
HALT-C Trial was therefore performed to determine whether viral suppression with
standard dose peginterferon and ribavirin followed by low dose peginterferon maintenance
therapy benefited patients with chronic hepatitis C and advanced fibrosis or cirrhosis.
PATIENTS AND METHODS
Patients and Study Design
The design of the HALT-C trial has been described previously (13). Briefly, 1,050 subjects
with bridging fibrosis or cirrhosis (Ishak fibrosis score 3–6) who were nonresponders to
prior treatment with interferon (with or without ribavirin) were retreated with standard dose
peginterferon alfa-2a and ribavirin. Subjects with detectable HCV RNA at week 20 were
defined as nonresponders and randomized to receive either 90 mcg/week of peginterferon
alfa-2a as maintenance therapy or to stop treatment and be followed as the control group.
Subjects with undetectable HCV RNA at treatment week 20 received up to 48 weeks of
peginterferon and ribavirin. The SVR rate achieved in this population, 18%, was previously
reported (15). Patients in whom virologic breakthrough occurred after week 20 or in whom
relapse occurred after 48 weeks of treatment were offered entry into the HALT-C Trial and
randomly assigned to receive maintenance therapy or no treatment. Both nonresponders and
breakthrough/relapsers were followed for 3.5 years after randomization. The current analysis
was restricted to 764 of the 813 patients treated during the lead-in phase and who entered the
randomized HALT-C trial. The 49 excluded patients either had no follow-up after
randomization, refused to remain on peginterferon if randomized to maintenance therapy, or
were treated with peginterferon outside the trial despite being randomized to the control
group. The 237 patients who entered the randomized HALT-C trial after receiving
peginterferon and ribavirin treatment outside the formal HALT-C Trial lead-in phase
(express patients) were also excluded because their quantitative HCV RNA response to
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treatment had not been assessed in the HALT-C Virology Core Laboratory. Clinical and
other laboratory data were collected from all subjects according to standard protocol-defined
procedures (13). Institutional Review Boards at all participating institutions approved the
study protocol and all amendments. Written informed consent was obtained from all subjects
prior to treatment.
Virologic Testing
Serum samples were obtained from all subjects at regular intervals, frozen at −70°C at each
clinical site and shipped at periodic intervals on dry ice to the Virology Core Laboratory.
HCV RNA was measured with both the quantitative Roche COBAS™ Amplicor HCV
Monitor Test, v. 2.0 assay (lower limit of detection (LLOD) 600 IU/ml; Roche Molecular
Systems, Branchburg, NJ) and, if negative, by the Roche COBAS Amplicor HCV Test, v.
2.0 assay (LLOD 100 IU/ml) as described previously (16). HCV genotypes were determined
with the INNO-LiPA HCV II kit (Siemens Medical Solutions Diagnostics, Tarrytown, NY).
For this retrospective analysis, patients were classified into three groups according to the
decline from pretreatment baseline in HCV RNA levels during the lead-in phase and after
randomization; <2 log10 decline, 2 to <4 log10, and ≥4 log10 decline in HCV RNA. The
baseline log10 HCV RNA level was the mean of the screening and pretreatment log10 HCV
RNA values. The log10 HCV RNA level during maintenance therapy was the mean of
values obtained at months 6, 12, 18, 24, 30 and 36 after randomization. Patients were also
grouped according to their mean serum HCV RNA level after randomization as follows:
≥100,000 IU/mL, <100,000-1,000 IU/mL and <1,000 IU/mL. Patients who were HCV RNA
negative by Roche Amplicor Monitor but positive by the Roche COBAS Amplicor HCV
assay were assigned a value of log10 2.78 (600 IU/ml) and patients who were negative by
both assays were assigned a value of log10 2.00.
Liver Histology
All patients underwent liver biopsy within 12 months prior to initiating peginterferon and
ribavirin treatment in the lead-in phase and at 18 and 42 months after randomization. All
biopsy specimens were reviewed by a team of 11 pathologists representing each of the
clinical centers and a central lead-pathologist. Each biopsy specimen was assigned a
consensus Ishak inflammatory and fibrosis score at group review sessions (17).
Definition of Outcomes
Protocl-defined clinical outcomes included an increase in the Child-Turcotte-Pugh (CTP)
score to ≥7 points on two consecutive study visits 3 months apart; development of ascites,
hepatic encephalopathy, variceal bleeding or spontaneous bacterial peritonitis; the
occurrence of HCC or death from any cause. For patients with bridging fibrosis (Ishak
fibrosis scores of 3 or 4) at study entry, a histologic endpoint, an increase by ≥2 points in the
Ishak fibrosis score at either of the two follow-up biopsies (18 or 42 months after
randomization) was also a primary outcome.
Statistical analyses
Analyses were performed with SAS® (Statistical Analysis Software, Cary, NC) version 9.1.
Baseline variables in the two treatment groups were compared with chi-square tests or t-
tests. Mixed models were used to evaluate the changes in HCV RNA over time. Kaplan-
Meier estimators were used to estimate clinical outcomes at 1,400 days (3.83 years) after
randomization and the rate of a ≥2 point increase in Ishak fibrosis score. Cox proportional
hazards regression analyses were performed to test the effects of lead-in treatment and
maintenance treatment on clinical outcomes. Complementary log-log regression analyses
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were performed to assess the effect of these treatments on the time to first 2-point increase
in Ishak fibrosis score. Analyses of clinical outcomes and changes in serum HCV RNA level
after randomization were restricted to patients who either had an outcome or were followed
for at least 36 months after randomization.
RESULTS
Patient groups
Table I summarizes the clinical, biochemical, virologic and histologic characteristics of the
HALT-C Trial patients included in this analysis grouped by randomization status to the
maintenance therapy arm or control arm. All patients received 24 weeks of peginterferon
and ribavirin during the lead-in phase, prior to randomization; 618 had detectable HCV
RNA in serum at week 20 and were classified as nonresponders, and 146 had undetectable
HCV RNA in serum at week 20 and entered the HALT-C Trial only after breakthrough
developed (N=30) or they relapsed (N=116). The mean duration of peginterferon and
ribavirin in the breakthough/relapse group was 48 weeks. The features of these 764 patients
were not significantly different from those of the entire HALT-C Trial cohort (14).
Figure 1 illustrates mean serum HCV RNA levels during the lead-phase and after
randomization throughout the HALT-C Trial for patients with nonresponse or breakthrough/
relapse. Of the 618 nonresponders who entered the trial 261 were still being followed in the
maintenance group and 253 in the control group by month 42. Nonresponders had a mean
decline in serum HCV RNA of 1.5 log10 IU/ml by the end of the 20 week lead-in phase
(Figure 1A). In patients randomized to stop therapy the mean serum HCV RNA level
returned to the pretreatment baseline. Patients randomized to remain on peginterferon
maintenance therapy had a significant reduction in serum HCV RNA levels compared to the
control group (p<0.0001); however, this reduction was only 0.56 log10 IU/ml (95% CI 0.50–
0.63) below the pretreatment baseline. Patients with breakthrough/relapse (N=146) had
undetectable HCV RNA in serum by week 20 in the lead-in phase and remained on
peginterferon and ribavirin until either breakthrough viremia developed before week 48 or
HCV RNA reappeared in serum after completing treatment. These patients were randomized
at variable times after the initiation of treatment depending upon the time of HCV RNA
recurrence. 42 months after randomization 73 patients remained in the control group and 59
patients in the maintenance therapy group. With breakthrough or relapse, the level of serum
HCV RNA increased to a mean of log10 6.0 IU/ml at the time of randomization.
Breakthrough/relapse patients randomized to stop treatment had a further increase in serum
HCV RNA back toward pretreatment baseline levels (Figure 1B). In contrast, patients with
breakthrough or relapse who initiated peginterferon maintenance therapy had a decline in
mean serum HCV RNA level that averaged 2.5 logs10 (95% CI 2.21–2.78) below the
pretreatment baseline throughout the maintenance phase. This decline was significantly
different than the change in serum HCV RNA level in the breakthrough/relapse patients
randomized to stop treatment (p<0.0001). During the 3.5 years of maintenance therapy the
mean serum HCV RNA level drifted up gradually relative to the pretreatment baseline from
a nadir of log10 −2.9 to −2.2 (p=0.0001).
Change in HCV RNA during the lead-in phase and impact on outcomes
Figure 2 illustrates the distribution of virologic responses observed during the lead-in phase.
Compared to their pretreatment baseline levels, 56% of patients had a <2 log10 decline in
serum HCV RNA with full-dose peginterferon and ribavirin; 21% had a 2 to <4 log10
decline and 23% had a ≥4 log10 reduction. Among patients with a ≥4 log10 decline in serum
HCV RNA, 82% were in the breakthrough/relapse group and had undetectable HCV RNA at
week 20.
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Figure 3 illustrates clinical outcomes that after randomization according to the decline in
serum HCV RNA during the lead-in phase. A significant (p=0.003) reduction in clinical
outcomes was observed with increasing degrees of viral suppression (Figure 3A). Clinical
outcomes developed in 21% of patients with <2 log10 decline in serum HCV RNA during
the lead-in phase (95% CI: 17–24%); 18% (95% CI: 12–24%) of patients with a 2 to <4
log10 decline and 8% (95% CI: 4–12%) of patients with ≥4 log10 decline. Clinical outcomes
also developed In 8% of the 146 patients with undetectable HCV RNA at the end of the
lead-in phase (a subset of the 178 patients with ≥4 log decline in HCV RNA). This decline
in the 3.5 year incidence of clinical outcomes was not significantly different between the
control and maintenance therapy groups (p=0.56). No effect of viral suppression during the
lead-in phase was observed on histologic outcome (Figure 3B). Overall, a ≥2-point increase
in fibrosis score on follow-up liver biopsy was observed in 24 and 33% of control and
maintenance patients, respectively, regardless of the degree of viral suppression (p=0.38). In
patients with undetectable HCV RNA at the end of the lead-in phase, fibrosis progression
was also observed in 23% and 28% of control and maintenance patients, respectively
(p=0.88).
Change in HCV RNA with maintenance peginterferon and impact on outcomes
Patients randomized to the control group had a rapid return in serum HCV RNA back to
their pretreatment baseline regardless of their viral response during the lead-in phase (Figure
1). Figure 4 illustrates the impact of continuing peginterferon maintenance therapy, at a
reduced dose of 90 mcg/week, on viral suppression. Over 97% (204/210) of patients with <2
log10 decline in serum HCV RNA during the lead-in phase had <2 log10 decline during the
maintenance phase. In patients with a 2 to <4 log10 decline in HCV RNA during the lead-in
phase, 86% had <2 log10 decline in HCV RNA during the maintenance phase. In patients
with ≥4 log10 decline in serum HCV RNA during the lead-in phase over half (46/88) could
not maintain viral suppression with half dose pegnterferon and failed to maintain HCV RNA
at levels <2 logs10 below their pretreatment baseline. Only 30/88 (34%) patients continued
to have marked viral suppression by ≥4 logs10 below their pretreatment baseline levels
during the maintenance phase, all but one of these maintained HCV RNA levels <1,0000 IU/
mL. These 30 patients accounted for 43% of the 69 patients who had undetectable HCV
RNA at the end of the lead-in phase.
Figure 5 illustrates clinical and histologic outcomes as a function of the decline in serum
HCV RNA during peginterferon maintenance therapy. Overall, no significant impact was
observed in clinical outcomes regardless of the degree of viral suppression. Although the
lowest frequency of clinical outcomes (13%) was observed in patients who maintained a ≥4
log10 decline in serum HCV RNA, this was not significantly different (p=0.74) than that
observed in patients with <4 log10 decline in serum HCV RNA during maintenance therapy
(18–23%). Similar results were obtained when clinical outcomes were evaluated with
respect to the mean absolute level of HCV RNA during maintenance therapy. Clinical
outcomes developed in 17% of patients with a mean serum HCV RNA of >100,000 IU/mL,
29% with a mean serum HCV RNA of 100,000-1,000 IU/mL and 18% with a mean serum
HCV RNA of <1,000 IU/mL. No significant impact of viral suppression was observed on
fibrosis progression (p=0.80). A histologic outcome was observed in 29% (95% CI 22%–
37%) of patients with <2 log10 decline in serum HCV RNA and in 25% (95% CI 6%–44%)
of patients with >4 log10 decline in HCV RNA during maintenance therapy. Fibrosis
progression was observed in 30% of patients when HCV RNA was suppressed to <1,000 IU/
mL during maintenance therapy.
Table 2 summarizes clinical outcomes that developed in patients who achieved a ≥4 log10
decline in serum HCV RNA during the lead-in phase and various degrees of viral
suppression during maintenance therapy. Because achieving a ≥4 log10 reduction in serum
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HCV RNA level during the lead-in phase was associated with significantly reduced
outcomes during the maintenance phase, the clinical outcomes in patients who achieved this
profound virologic suppression but were randomized to the control group were also
examined. Patients with clinical complications of liver disease and liver related mortality
were separated from those in whom the trial endpoint reached was only an increase in CTP
score without a discrete clinical complication and from patients with non-liver related death.
Patients with a clinical complication of liver disease were included in the liver-complication
category even if they also had a CTP score increase or a non-liver related death. Overall,
complications of liver disease developed in 5.5% of patients with a ≥4 log decline in serum
HCV RNA during the lead-in phase who were then randomized to stop treatment and in
4.3% of patients without viral suppression (serum HCV RNA remained <2 logs10 below the
pre-treatment baseline) despite receiving peginterferon maintenance therapy. A clinical
complication of liver disease developed in only 1/30 patients (3.3%) who experienced viral
suppression by ≥4 logs10 during both the lead-in phase and maintenance therapy. This single
patient had undetectable HCV RNA at the end of the lead-in phase and during maintenance
therapy. Patients who lost detectable HCV RNA during the lead-in phase with subsequent
breakthrough/relapse were treated for 48 weeks (figure 1). Clinical outcomes developed in
7.5% (11/146) of these patients versus 3/32 (9.3%) patients who had a >4 log decline in
HCV RNA but failed to clear HCV RNA and were treated for only 24 weeks (p=0.81).
Of the 69 patients with undetectable HCV RNA at the end of the lead-in phase, 25 were
repeatedly (more than 3/7 values between months 12–48) HCV RNA undetectable during
maintenance therapy. Thirteen (52%) of these patients achieved an SVR and 5 (20%)
relapsed when peginterferon alfa was discontinued after 3.5 years. The remaining patients
experienced breakthrough viremia or dropped out of the trial while on maintenance therapy.
DISCUSSION
The HALT-C Trial was a prospective, randomized controlled study designed to determine if
continuing peginterferon alfa-2a at a dose of 90 mcg/week over 3.5 years could reduce
complications of cirrhosis, HCC and mortality in patients with chronic hepatitis C and
advanced bridging fibrosis or cirrhosis who had failed to achieve an SVR following
treatment with peginterferon and ribavirin. Unfortunately, no overall reduction in any of
these clinical endpoints was achieved (14). The results of two similar studies, CO-PILOT
and EPIC3, were also reported recently (18,19). In the CO-PILOT Trial no lead-in treatment
phase preceeded randomization; patients with advanced fibrosis or cirrhosis who were
nonresponders to either standard or peginterferon with or without ribavirin were randomized
to receive either peginterferon alfa-2b at a dose of 0.5 mcg/kg/week or colchicine for 4
years. The study design of the EPIC3 Trial was similar to that of the HALT-C Trial; subjects
entered a lead-in treatment phase of peginterferon alfa-2b and weight-based ribavirin after
which nonresponders were randomized to receive either peginterferon alfa-2b at a dose of
0.5 mcg/kg/week or no treatment for up to 3 years. Despite differences in study design, the
results of the CO-PILOT and EPIC3 Trials were very similar to those observed in the
HALT-C Trial; no overall benefit of peginterferon maintenance therapy was observed. In
EPIC3 a significant reduction in variceal bleeding was observed in the subset of patients
with esophageal varices suggesting that peginterferon may affect portal pressure. A recent
substudy of the HALT-C Trial has demonstrated that peginterferon alfa-2a 90 mcg/week
lowers portal pressure in patients with a baseline portal hypertension and esophageal varices
(20). However, maintenance therapy in the HALT-C Trial was not associated with a
reduction in variceal hemorrhage.
Before these three large trials of maintenance therapy were initiated, a preliminary study of
maintenance therapy with standard interferon alfa-2b (3 mU three times weekly) did suggest
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that a maintenance approach might be effective (12). In that study, however, only patients
who achieved a histologic response (defined as a 50% decline in the hepatic inflammation
score) after 6 months of interferon therapy were eligible for enrollment. This improvement
in liver inflammation was associated with a marked decline in serum HCV RNA level
(9,12). Continuing interferon in these patients maintained both histologic improvement and
suppression of serum HCV RNA. Stopping interferon was associated with a rapid rise in
serum HCV RNA back to the pretreatment baseline and a worsening in hepatic
inflammation scores. Unlike the HALT-C, CO-PILOT or EPIC3 Trials, the majority of
patients in this preliminary study did not have advanced fibrosis or cirrhosis, the trial lasted
only 2 years, and the impact of treatment on morbidity and mortality was not assessed.
The study designs of the three large maintenance therapy trials did not require either prior
histologic or virologic responses as criteria for inclusion. In addition, the dose of
peginterferon in these trials (half-dose peginterferon alfa-2a and one-third the standard dose
of peginterferon alfa-2b) was selected based upon tolerability over an extended treatment
duration, not efficacy in achieving HCV RNA suppression. Only 23% of patients enrolled in
the HALT-C Trial had profound viral suppression (a ≥4 log10 decline in serum HCV RNA
level) with full dose peginterferon and ribavirin during the lead-in phase and only 30 (8%)
patients maintained profound viral suppression during maintenance therapy. Serum levels of
HCV RNA were not assessed in the CO-PILOT Trial and data on viral suppression during
the EPIC3 Trial are not currently available. Thus, although the primary analysis of the
HALT-C, CO-PILOT and EPIC3 trials demonstrated that peginterferon maintenance therapy
provided no overall benefit to patients with chronic hepatitis C, none of these studies was
designed to address whether profound viral suppression with maintenance peginterferon
therapy to keep HCV RNA undetectable or near undetectable had the potential to prevent
complications of advanced hepatic fibrosis.
The present analysis was performed to investigate the relationship between viral suppression
and outcomes during the HALT-C Trial. Our results demonstrate that viral suppression with
standard doses of peginterferon and ribavirin during the 24-week lead-in phase was
associated with a significant reduction in clinical outcomes during the ensuing 3.5 years
regardless of whether patients received maintenance peginterferon therapy or not. Several
previous studies have suggested that patients who are treated with even a single, brief course
of interferon-based therapy have a reduction in HCC and improved mortality (10,11). The
present study also suggests that profound viral suppression, even for a relatively brief period
of time, is associated with clinical benefit.
Data from the present analysis also demonstrated that over half the patients with profound
viral suppression during standard dose peginterferon/ribavirin could not maintain this
virologic response when ribavirin was stopped and the peginterferon dose was reduced by
half. The rate of liver related outcomes observed in these patients was similar to that
observed for patients who also achieved profound virologic suppression during the lead-in
phase and were randomized to stop treatment (4.3% versus 5.6%). Only 30 patients had
persistent suppression of HCV RNA by ≥4 log10 with half-dose peginterferon maintenance
therapy. Although a complication of cirrhosis developed in only 1 of these patients (3.3%)
the number of patients was not sufficient to demonstrate with any confidence that persistent
suppression of HCV RNA, even to undetectable levels, was associated with a reduction in
clinical outcomes.
The few patients in this study who appeared to benefit the most from peginterferon
maintenance therapy in this study were the ones who responded to full dose peginterferon
and ribavirin during the lead-in phase but experienced either breakthrough or relapse. As has
been well established, the relapse rate after antiviral therapy for chronic hepatitis C is
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inversely proportional to the rapidity with which HCV RNA becomes undetectable during
treatment (21,22). The vast majority of patients who relapse do not loose detectable HCV
RNA until they have received 12–24 weeks of treatment. Several recent studies have
demonstrated that continuing peginterferon and ribavirin for a longer duration, up to 72
weeks, in patients with genotype 1 and delayed clearance of HCV RNA can reduce relapse
and increase SVR significantly (23,24). Unfortunately, many patients with advanced fibrosis
or cirrhosis are unable to tolerate prolonged treatment with full doses of peginterferon and
ribavirin. Data from the HALT-C Trial suggest that if such patients could be kept HCV
RNA undetectable on half-dose peginterferon maintenance therapy for 3.5 years, an SVR of
approximately 52% could be achieved.
The results of this analysis lay the foundation for future studies of maintenance therapy, not
with peginterferon, but with potent oral protease and polymerase inhibitors of HCV. Several
such agents are currently in various phases of development and when combined with
peginterferon and ribavirin yield SVR rates that are significantly higher than those observed
with peginterferon and ribavirin alone (25–27). Despite promising results with these agents,
all patients with chronic hepatitis C are unlikely to be cured with a combination of one or
more oral HCV inhibitors plus peginterferon and ribavirin in the future. Thus, a group of
patients with advanced fibrosis or cirrhosis will eventually require multi-drug antiviral
regimens to achieve long term suppression of HCV RNA. Whether such patients could
achieve an SVR with multi-drug oral agents without peginterferon remains to be determined.
In summary, this analysis has demonstrated that profound viral suppression by more than 4
logs10 with full-dose peginterferon and ribavirin was associated with a significant decline in
clinical outcomes over the next 3.5 years. Continuing half-dose peginterferon-alfa 2a as
maintenance therapy did not affect the development of clinical outcomes regardless of the
degree of viral suppression achieved during the lead-in phase. This analysis confirms that no
rationale exists for maintenance peginterferon therapy among patients in whom HCV RNA
cannot be suppressed to undetectable levels. Our data did show, however, that an SVR of
approximately 50% was achieved in the few patients who became HCV RNA undetectable
during the lead-in phase, experienced breakthrough or relapse and then remained
persistently HCV RNA negative during maintenance peginterferon for 3.5 years.
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Figure 1.
Change in serum HCV RNA level over time. During the lead-in phase (stippled area)
patients were treated with peginterferon alfa-2a 180 mcg/ml and ribavirin. (A)
Nonresponder group: Patients were serum HCV RNA- positive at week 20. At treatment
week 24 (month 0) these patients were randomized to either peginterferon alfa-2a 90 mcg/ml
maintenance therapy without ribavirin or to the no treatment control group. (B)
Breakthrough/relapse group: Patients had undetectable serum HCV RNA at week 20. These
patients received up to 48 weeks of treatment and were randomized (month 0) to either
peginterferon alfa-2a 90 mcg/ml maintenance therapy or to the no treatment control group
after breakthrough or relapse occurred. For simplicity, and for comparison with the
nonresponder group, the time listed on the x-axis corresponds to months after
randomization. The wider lead-in phase (stippled area) along the x-axis in the breakthrough/
relapse group reflects the longer duration of treatment these patients received prior to
randomization.
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Figure 2.
Number of patients who achieved serum HCV RNA suppression to varying degrees during
the lead-in phase. Among patients with a ≥4 log10 decline in serum HCV RNA at the end of
the lead-in phase, 77/90 (86%) who entered the control arm and 69/88 (78%) randomized to
maintenance peginterferon had undetectable serum HCV RNA at week 20 and received up
to 48 weeks of treatment. Numbers at the bottom of each bar represent the number of
patients in each group.
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Figure 3.
Impact of viral suppression during the lead-in phase on clinical (A) and fibrosis (B)
outcomes after randomization. Patients were grouped according to the degree of viral
suppression during the lead-in phase. Panel A: A significant reduction in clinical outcomes
was associated with a decline in serum HCV RNA during the lead-in phase (p=0.003). No
difference in clinical outcomes existed between the control and maintenance therapy groups
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(p=0.56). Panel B: No significant reduction in fibrosis outcome was associated with a
decline in serum HCV RNA during the lead-in phase (p=0.42). No difference in outcomes
existed between the control and maintenance therapy groups (p=0.88). Numbers at the
bottom of each bar represent the number of patients in each group. Error bars indicate the
standard error.
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Figure 4.
Percent of patients with a decline in serum HCV RNA by various log10 amounts from the
pretreatment baseline while receiving peginterferon (90 mcg/week) maintenance therapy.
The mean log10 HCV RNA over the first 3 years of maintenance therapy was used for this
assessment. Patients were grouped according to their decline in serum log10 HCV RNA
from the pre-treatment baseline during the lead-in phase. Numbers of patients in each group:
< 2 log10 = 210, 2–4 log10 = 80, ≥ 4 log10 = 88.
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Figure 5.
Impact of serum HCV RNA level during peginterferon (90 mcg/week) maintenance therapy
on clinical and fibrosis outcomes (% ± SE). Patients were grouped according to the mean
decline in serum HCV RNA level from the pretreatment baseline after randomization. No
significant reductions in clinical outcomes (p=0.74) or fibrosis outcomes (p=0.80) were
observed with increasing amounts of viral suppression during maintenance therapy.
Numbers at the bottom of each bar represent the number of patients in each group.
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TABLE I
CLINICAL CHARACTERISTICS OF THE PATIENT POPULATION
Control Maintenance p
N 386 378
Age (years) 49.5 ± 7.3 50.8 ± 7.3 0.01
Male (%) 70% 72% 0.65
Race (%Caucasian) 70% 72% 0.49
Baseline ALT (IU/l) 116 ± 87 107 ± 78 0.14
Baseline WBC (cels/mm3) 5.7 ± 1.8 5.9 ± 1.9 0.19
Baseline platelet count (cells/mm3) 167 ± 68 166 ± 62 0.87
Genotype 1 (%) 92% 95% 0.09
Baseline log10 HCV RNA (IU/ml) 6.44 ± 0.48 6.46 ± 0.45 0.45
Cirrhosis (%) 40% 40% 0.95
Virologic response during lead-in:
 Non-response (%) 80% 82% 0.55
 Breakthrough or relapse (%) 20% 18%
Values are given as means ± standard deviation or as the percentage of patients in each group.
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TABLE 2
OUTCOMES OBSERVED IN PATIENTS WITH A >4 LOG10 DECLINE IN SERUM HCV RNA DURING
THE LEAD-IN PHASE AND VARYING DEGREES OF HCV RNA SUPPRESSION DURING
PEGINTERFERON MAINTENANCE THERAPY
Decline in serum HCV RNA by ≥4 logs10 during the lead-in phase
Control Group Log10 decline in serum HCV RNA from the pre-treatment baseline during the
maintenance phase by:
<2 2 to <4 ≥4
N 90 46 12 30
Death - not liver related 0 1 (2.2%) 0 1 (3.3%)
Increase in CTP score
only
3 (3.3%) 0 0 1 (3.3%)
Complication of
cirrhosis or liver related
death
5 (5.6%) 2 (4.3%) 0 1 (3.3%)
Outcomes occurred in 11/146 (7.5%) patients with breakthrough/relapse and treated for 48 weeks during the lead-in phase and 3/32 (9.3%) patients
without virologic response treated for only 24 weeks.
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